CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
OS by PS in Metastatic Pancreatic Cancer Treatment- Data From an Exploratory Subgroup Analysis
<< View More Conferences
2015 SMR Congress
Oncology Conference Multimedia
View more videos >>
Dr. Schadendorf on Nivolumab/ Ipilimumab Combination Trial in Melanoma
Dr. Georgina Long on Dabrafenib and Trametinib in BRAF-Mutated Melanoma
Dr. Atkinson on When to Use Nivolumab Monotherapy Versus Nivolumab/Ipilimumab Combination
Oncology Conference Articles
Vemurafenib/Cobimetinib Shows 30% OS Benefit in BRAF-Mutant Melanoma
Treatment with the combination of vemurafenib and cobimetinib improved overall survival by 4.9 months compared with vemurafenib alone for patients with BRAF mutation-positive advanced melanoma.
Pembrolizumab/Ipilimumab Combo Effective in Advanced Melanoma
A treatment regimen of pembrolizumab plus low-dose ipilimumab was tolerable and effective for patients with advanced melanoma.
Factors Affecting Dabrafenib/Trametinib Outcomes in Melanoma Identified
In the largest-to-date analysis of treatment-naÃ¯ve metastatic melanoma patients with BRAF V600 mutations treated with dabrafenib and trametinib, researchers have found that baseline LDH levels and number of disease sites were the most significant factors affecting survival.
Novel Pembrolizumab Combos Show Promising Responses in Melanoma
Two separate early phase clinical trials exploring pembrolizumab-containing immunotherapy combinations have shown objective response rates over 50% in patients with advanced melanoma.
Understanding BRAF Resistance Critical to Advancing Melanoma Care
Making real strides in melanoma care requires an understanding of BRAF resistance mechanisms.
James Allison Predicts 'Cures' With Checkpoint Inhibitor Combinations
Since the approval of the first checkpoint inhibitor, ipilimumab, several combinations and monotherapies have gained rapid approval, with continued expansion on the horizon.
Nivolumab Survival Benefit Sustained in Long-Term Melanoma Data
Long-term data continue to show sustained improvements in overall survival with nivolumab alone or in combination with ipilimumab as a frontline treatment for patients with advanced melanoma.
Novel Agents, T-VEC Combos Mark Next Phase of Oncolytic Immunotherapy Era in Melanoma
With the FDA approval of the first oncolytic immunotherapy-talimogene laherparepvec (T-VEC; Imlygic)-the stage has been set for increased research into these agents.
QoL Similar With Checkpoint Combo Versus Single-Agents in Melanoma
There were few differences in quality of life, global health, and symptom burden between patients with melanoma who were treated with nivolumab plus ipilimumab or either agent alone.
Researchers Seek to Improve Responses With Checkpoint Inhibitors
Predictive genetic signatures and novel combination strategies may be the key to improving the often dramatic responses seen with immune checkpoint inhibitors.
New Treatments for Novel Targets Next Step in Immuno-Oncology Revolution
There is a wide variety of novel targets and corresponding checkpoint and immune blocker/activator therapies that may soon show promise in cancer care.
Overcoming Challenges in the Management of mCRC
Novel Agents Spark New Approaches for Triple-Negative Breast Cancer
FDA Grants Avelumab/Axitinib Combo Priority Review for RCC
FDA Grants Pembrolizumab/Axitinib Combo Priority Review for Frontline RCC
Brahmer Calls for Better Incorporation of Precision Medicine in Lung Cancer
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.